Cargando…
Development and 10-year history of a biosimilar: the example of Binocrit(®)
Patent expirations for several biological products have prompted the development of alternative versions, termed ‘biosimilars’, which have comparable quality, safety and efficacy to a licensed biological medicine (also referred to as the ‘reference’ medicine). The first biosimilars developed in onco...
Autores principales: | Aapro, Matti, Krendyukov, Andriy, Höbel, Nadja, Seidl, Andreas, Gascón, Pere |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5912267/ https://www.ncbi.nlm.nih.gov/pubmed/29707043 http://dx.doi.org/10.1177/1758835918768419 |
Ejemplares similares
-
Treatment patterns and outcomes in patients with non‐small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy‐induced/febrile neutropaenia: Results from the MONITOR‐GCSF study
por: Aapro, Matti, et al.
Publicado: (2019) -
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
por: Aapro, Matti, et al.
Publicado: (2018) -
Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim
por: Gascon, Pere, et al.
Publicado: (2019) -
HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience
por: Dellanna, Frank, et al.
Publicado: (2017) -
Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer
por: Krendyukov, A., et al.
Publicado: (2017)